SinoMab BioScience Schwankungsanfälligkeit
Was ist das Schwankungsanfälligkeit von SinoMab BioScience?
Schwankungsanfälligkeit von SinoMab BioScience Limited ist 9.48%
Was ist die Definition von Schwankungsanfälligkeit?
Die Schwankungsanfälligkeit oder Prozent des durchschnittlichen wahren Bereichs (ATRP 14) ist die ATR, ausgedrückt als Prozentsatz des Schlusskurses.
Average true range percent (ATRP) measures volatility on a relative level. This is opposed to the ATR, which measures volatility on an absolute level. ATRP allows securities to be compared whereas ATR does not. That means lower-priced stocks won't necessarily have lower ATR values than higher-priced stocks.
The period used in the calculation is 14 days and the normalized indicator oscillates between 0 and 100 percent of recent price variation. Importantly, the indicator doesn't predict the direction of price but it describes the current volatility. The volatility is comparable across all securities and all markets.
Volatility expresses the degree of price movement. The use of ATRP as volatility compared to ATR is preferred in cases when different securities or different time periods are compared. Examples are stock screening, filtering strategies, and studying seasonality and volatility patterns over long periods of time and different markets
Schwankungsanfälligkeit von Unternehmen in Health Care Sektor auf HKSE im Vergleich zu SinoMab BioScience
Was macht SinoMab BioScience?
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Unternehmen mit schwankungsanfälligkeit ähnlich SinoMab BioScience
- American National Bankshares hat Schwankungsanfälligkeit von 9.47%
- Safestore plc hat Schwankungsanfälligkeit von 9.47%
- Third Point Offshore Investors hat Schwankungsanfälligkeit von 9.47%
- Liberty Gold hat Schwankungsanfälligkeit von 9.47%
- China Kingstone Mining hat Schwankungsanfälligkeit von 9.47%
- Passage Bio Inc hat Schwankungsanfälligkeit von 9.47%
- SinoMab BioScience hat Schwankungsanfälligkeit von 9.48%
- Nevada King Gold hat Schwankungsanfälligkeit von 9.49%
- Great Northern Minerals hat Schwankungsanfälligkeit von 9.49%
- GraniteShares 3x Short BAE Systems Daily ETC hat Schwankungsanfälligkeit von 9.49%
- Canopy Growth hat Schwankungsanfälligkeit von 9.50%
- Blend Labs hat Schwankungsanfälligkeit von 9.50%
- Celamin hat Schwankungsanfälligkeit von 9.50%